Pfizer launches Elranatamab to expand treatment options for Multiple Myeloma in India

Pfizer has announced the launch of a new therapy, a BCMA (B-Cell Maturation Antigen) directed bi-specific antibody in India for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).

The new medication, for those who have received 4 prior therapies, delivers a clinically meaningful improvement in progression-free survival (PFS) and a durable response for RRMM Patients, while maintaining an established safety profile.

Elranatamab is now available in India as a ready-to-use, convenient fixed-dose subcutaneous injection. It offers the option of weekly administration, followed by every-other-week dosing for patients who respond after 24 weeks of weekly treatment. Subcutaneous administration results in less time spent at the clinic for the patient and the caregiver, to have the treatment administered.

This therapy sets a new standard in comprehensive multiple myeloma care by providing a new option for heavily pre-treated patients. Elranatamab provides a therapy that effectively activates the body's immune system to attack cancer cells. It destroys cancer cells by binding to both CD3, a protein found on the surface of T cells (a type of white blood cell), and BCMA, a protein found on the surface of B cells (a second type of white blood cell).

Multiple myeloma, that ranks as the second most common type of blood cancer globally, also poses a significant challenge in India, being an aggressive and currently incurable blood cancer.